Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

Nuovi progressi nel trattamento del cancro alla prostata: Darolutamide sta per essere approvato nell’UE

Non destinato ai media statunitensi e britannici (NOTIZIA IN BREVE) Il comitato per i medicinali per uso umano dell’Agenzia europea per i medicinali ha raccomandato l’autorizzazione all’immissione in commercio nell’Unione europea di darolutamide, un inibitore orale del recettore degli androgeni, … Read the full press release

New Advancement in Prostate Cancer Treatment: Darolutamide Set to be Approved in EU

Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended darolutamide, an oral androgen receptor inhibitor, for marketing authorization in the European Union as a treatment for patients … Read the full press release

Sandoz acquires Mycamine, reinforcing its anti-infectives portfolio

(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release

Sandoz adquiere Mycamine, reforzando su cartera de antiinfecciosos

(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release

TUM Researchers Develop New Methods for Investigating Neuronal Patterns in Cognitive Mental Disorders

How can physicians help patients suffering from mental health disorders like chronic pain, depression and stroke? (IN BRIEF) An interdisciplinary team of researchers at TUM is developing new methods to investigate the neuronal patterns underlying cognitive mental disorders such as … Read the full press release

Investigadores de TUM desarrollan nuevos métodos para investigar patrones neuronales en trastornos mentales cognitivos

¿Cómo pueden los médicos ayudar a los pacientes que padecen trastornos de salud mental como dolor crónico, depresión y accidente cerebrovascular? (NOTICIA EN BREVE) Un equipo interdisciplinario de investigadores de TUM está desarrollando nuevos métodos para investigar los patrones neuronales … Read the full press release

Team of Experts from University of Liverpool Spin-Out Sulantrix Using AI and Multi-omics Platforms to Develop New Cancer Treatments

(IN BRIEF) A new spin-out drug discovery company from the University of Liverpool called Sulantrix is exploring new cancer medicines targeting previously untapped classes of pseudoenzymes. The company is led by Professor Patrick Eyers and CEO David Williams, who has … Read the full press release

Équipe d’experts de l’Université de Liverpool Spin-Out Sulantrix utilisant des plateformes d’IA et multi-omiques pour développer de nouveaux traitements contre le cancer

(ACTUALITÉ EN BREF) Une nouvelle société dérivée de découverte de médicaments de l’Université de Liverpool appelée Sulantrix explore de nouveaux médicaments contre le cancer ciblant des classes de pseudoenzymes jusqu’alors inexploitées. La société est dirigée par le professeur Patrick Eyers … Read the full press release

Roche’s Tecentriq and Avastin Combination Offers New Hope for Early-Stage Liver Cancer Patients

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, announced that their combination treatment … Read the full press release

L’association Tecentriq et Avastin de Roche offre un nouvel espoir aux patients atteints d’un cancer du foie à un stade précoce

Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BÂLE, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionnier mondial des produits pharmaceutiques et des diagnostics axé sur l’avancement de la science pour améliorer la vie des … Read the full press release

Boehringer Ingelheim: A Model for Employee Wellbeing in the Corporate World

(PRESS RELEASE) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies with 130 years of experience, has announced it has been named a “Global Top Employer” for the third year in a row by the … Read the full press release

Boehringer Ingelheim: un modelo para el bienestar de los empleados en el mundo corporativo

(COMUNICADO DE PRENSA) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, una de las principales compañías farmacéuticas del mundo impulsadas por la investigación con 130 años de experiencia, ha anunciado que ha sido nombrada “Global Top Employer” por tercer año consecutivo por … Read the full press release

AstraZeneca completes acquisition of Neogene Therapeutics, expanding its portfolio in immuno-oncology

(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release

AstraZeneca completa la adquisición de Neogene Therapeutics, ampliando su cartera en inmunooncología

(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado la finalización de su adquisición de Neogene Therapeutics Inc. Neogene es una compañía global de biotecnología en etapa clínica que … Read the full press release

AstraZeneca’s Tezspire receives EU approval for self-administration in a convenient pre-filled pen for severe asthma patients

(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release

Tezspire de AstraZeneca recibe la aprobación de la UE para la autoadministración en una práctica pluma precargada para pacientes con asma grave

(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release

Roche’s Xofluza: The Breakthrough Influenza Drug Approved for Children in Europe

(PRESS RELEASE) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, has announced that the European Commission has approved Xofluza (baloxavir marboxil), a … Read the full press release

Xofluza de Roche: el fármaco innovador contra la gripe aprobado para niños en Europa

(COMUNICADO DE PRENSA) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionero mundial en productos farmacéuticos y diagnóstico centrado en el avance de la ciencia para mejorar la vida de las personas, ha anunciado que la … Read the full press release

Bayer: Viralgen Vector Core Licensed for Large-Scale recombinant adeno-associated virus (rAAV) Gene Therapy Production

(PRESS RELEASE) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), a global enterprise with core competencies in the life science fields of healthcare and nutrition and and one of the largest pharmaceutical companies in the world, has announced … Read the full press release

Bayer: Viralgen Vector Core con licencia para la producción de terapia génica de virus adenoasociados recombinantes (rAAV) a gran escala

(COMUNICADO DE PRENSA) SAN SEBASTIAN, Spain, 9-Jan-2023 — /EuropaWire/ — Bayer (ETR: BAYN), una empresa global con competencias básicas en los campos de las ciencias biológicas de la salud y la nutrición y una de las compañías farmacéuticas más grandes … Read the full press release

Sanofi releases Q4 2022 Memorandum for investors to use in financial modeling

(PRESS RELEASE) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), a global biopharmaceutical company focused on human health, has announced that its Q4 2022 Memorandum for modelling purposes is now available on the “Investors” page of the company’s website. This … Read the full press release

Sanofi veröffentlicht das Q4 2022 Memorandum für Investoren zur Verwendung bei der Finanzmodellierung

(PRESSEMITTEILUNG) PARIS, 4-Jan-2023 — /EuropaWire/ — Sanofi (EPA: SAN), ein globales biopharmazeutisches Unternehmen, das sich auf die menschliche Gesundheit konzentriert, hat bekannt gegeben, dass sein Memorandum für das 4. Quartal 2022 zu Modellierungszwecken jetzt auf der Seite „Investoren“ der Website … Read the full press release

EQT BPEA V Fund to exit from Bushu Pharmaceuticals, one of the leading CDMOs in Japan

(PRESS RELEASE) STOCKHOLM, 20-Dec-2022 — /EuropaWire/ — EQT, a purpose-driven global investment organization, has announced that its BPEA V Fund will divest Bushu Pharmaceuticals, a leading CMO in Japan that produces high-quality pharmaceutical and medical devices, by selling it to … Read the full press release

EQT BPEA V Fund se retire de Bushu Pharmaceuticals, l’un des principaux CDMO au Japon

(COMMUNIQUÉ DE PRESSE) STOCKHOLM, 20-Dec-2022 — /EuropaWire/ — EQT, une organisation d’investissement mondiale axée sur les objectifs, a annoncé que son fonds BPEA V cèdera Bushu Pharmaceuticals, un chef de file du marketing au Japon qui produit des des dispositifs … Read the full press release

The European Investment Bank (EIB) to support the Spanish medical diagnostics company DeepUll with EUR 20 million loan

The EIB and DeepUll have signed a EUR 20m loan agreement to finance research, development and innovation. The EU financing will enable the development of an automated diagnostics device, leading to faster and more accurate early sepsis diagnosis. The EIB … Read the full press release

El Banco Europeo de Inversiones (BEI) apoyará a la empresa española de diagnóstico médico DeepUll con un préstamo de EUR 20 millones

El BEI y DeepUll han firmado un acuerdo de préstamo de 20 millones de EUR para financiar la investigación, el desarrollo y la innovación. La financiación de la UE permitirá el desarrollo de un dispositivo de diagnóstico automatizado, lo que … Read the full press release

EQT Future fund part of a consortium of investors acquiring a minority stake in drug delivery solutions provider SHL Medical

(PRESS RELEASE) STOCKHOLM, 9-Dec-2022 — /EuropaWire/ — EQT, a purpose-driven global investment organization, has announced that its EQT Future fund, the firm’s new impact-driven longer-hold investment strategy, is co-investing in the SHL Medical, a world-leading provider of drug delivery solutions. … Read the full press release

Le fonds EQT Future fait partie d’un consortium d’investisseurs acquérant une participation minoritaire dans le fournisseur de solutions d’administration de médicaments SHL Medical

(COMMUNIQUÉ DE PRESSE) STOCKHOLM, 9-Dec-2022 — /EuropaWire/ — EQT, une organisation d’investissement mondiale axée sur les objectifs, a annoncé que son fonds EQT Future, la nouvelle stratégie d’investissement à long terme axée sur l’impact, est co-investissant dans SHL Medical, l’un … Read the full press release

Roche Diagnostics: Globally, up to 75 percent of people living with Alzheimer’s disease have not been diagnosed

The company announces FDA clearance for its Alzheimer’s disease Cerebrospinal Fluid (CSF) assays The Elecsys® Alzheimer’s disease (AD) CSF assays will be available on the cobas fully automated immunoassay analyzers, enabling patients to get broad access to high quality testing in a timely … Read the full press release

Roche Diagnostics: a nivel mundial, hasta el 75 por ciento de las personas que viven con la enfermedad de Alzheimer no han sido diagnosticadas

La compañía anuncia la aprobación de la FDA para sus ensayos de líquido cefalorraquídeo (LCR) para la enfermedad de Alzheimer Los ensayos Elecsys® para la enfermedad de Alzheimer (EA) en LCR estarán disponibles en los analizadores de inmunoensayo totalmente automatizados … Read the full press release